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Abstract
Background: Individuals suffering from spinal cord injury (SCI) are at higher risk for respiratory-related viral
infections such as influenza. In a previous study (Zha et al., J Neuroinflammation 11:65, 2014), we demonstrated
that chronic spinal cord injury caused impairment in CD8+T cell function with increased expression of the
immunosuppressive protein, programmed cell death 1 (PD-1). The present study was undertaken to establish
whether chronic SCI-induced immune deficits would affect antiviral immunity directed against primary and
secondary infections.
Methods: Six to seven weeks following a SCI contusion at thoracic level T9, mice were infected intranasally
with influenza virus. Virus-specific immunity was analyzed at various time points post-infection and compared
to uninjured controls.
Results: We report that chronic thoracic SCI impairs the ability of the animals to mount an adequate antiviral
immune response. While all uninjured control mice cleared the virus from their lungs by day 10 post-infection,
a significant number (approximately 70 %) of chronic SCI mice did not clear the virus and succumbed to
infection-induced mortality. This was attributed to severe deficits in both virus-specific antibody production
and CD8+ T cell response in injured mice after primary infection. We also determined that previously acquired
humoral immunity was maintained after spinal cord injury as vaccination against influenza A prior to injury-protected
mice from a homologous viral challenge. In contrast, prior immunization did not protect mice from a heterotypic
challenge with a different strain of influenza virus.
Conclusions: Taken together, our data demonstrate that chronic SCI attenuates virus-specific humoral and cellular
immunity during the establishment of primary response and impairs the development of memory CD8+ T cells. In
contrast, B cell memory acquired through vaccination prior to SCI is preserved after injury which demonstrates that
antigen-specific memory cells are refractory following injury. Our study defines important parameters of the deficits of
chronic SCI-induced immune depression during a viral respiratory infection. Our objective is to better understand the
mechanisms of spinal cord injury-induced immune depression with the goal of developing more effective therapies
and reduce mortality due to complications from influenza and other infections.
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Background
Central nervous system (CNS) injury such as spinal cord
injury (SCI) disrupts the crosstalk between the CNS and
the immune system resulting in a syndrome called “CNS
Injury-Induced Immuno-depression” (CIDS) characterized
by increased susceptibility to infections, worse neuro-
logical outcome, and oftentimes death [1, 2]. In fact, more
than 50 % of deaths following SCI result from infection [1,
3–5]. Investigations on the effects of SCI on peripheral im-
mune function have yielded valuable insights regarding
the negative impact of loss of proper regulation by periph-
eral nerves on primary and secondary lymphoid tissues.
Inflammation and stress responses initiated soon after in-
jury can cause an early deficit in leukocyte number and
function [6]. Clinical and experimental models of SCI have
validated that during the acute phase of injury, post-SCI
both innate and adaptive immunity are severely com-
promised [6–8] and can persist into the chronic phase
[4, 9–11]. While most studies investigating the impact
of acute or chronic SCI on immune dysfunction have
focused on high thoracic (T3) injury, studies by Held
and colleagues have concluded that increased sensitivity to
viral infection due to SCI-induced immune depression is
level independent [4]. Therefore, it is critical to better
understand mechanisms through which SCI mediates sys-
temic immune depression so that complications arising
from secondary infections (e.g., chronic hospitalization,
worse neurological outcome, and death) can be reduced or
alleviated altogether. A number of studies examining SCI-
induced immune depression have shown an increase in the
susceptibility to microbial infections such as mouse hepa-
titis virus [4] and Streptococcus pneumoniae [12]. However,
few have examined the impact of SCI on antiviral immunity
using a clinically relevant respiratory virus infection model.
For example, SCI patients are at high risk of developing
complications of influenza infection followed by secondary
pneumonia due to their reduced respiratory function and
mobility after injury [3, 13–15]. Influenza A virus is a major
respiratory pathogen that causes high morbidity and ac-
counts for a significant number of deaths in both the very
young and elderly people (www.cdc.gov). Furthermore, the
emergence of new pandemic strains in the past decade have
heightened the awareness that immune-compromised pa-
tients such as those suffering from SCI are most susceptible
to new viruses [16]. In immunocompetent individuals, pri-
mary infection generates a robust immunity and requires
generation of both virus-specific antibodies and an effector
T cell response [17]. This establishes an immunological
memory and an immune protection over an individual’s
lifespan that can protect against re-infection with the same
virus. This response can also be mimicked by proper
immunization.
Thus, the goal of this study was to characterize how
chronic SCI affects immunity acquired after influenza
infection. We used a well-characterized mouse model of
influenza virus infection in C57Bl/6J mice [18] to inves-
tigate the mechanisms of protective immunity in chronic
SCI during primary and secondary viral infections. Intra-
nasal inoculation with type A influenza virus results in a
lower respiratory tract infection and induction of both
innate and adaptive responses necessary to clear the viral
infection. Because of the complex nature of SCI and the
finding that high-level injury affects immune function
through complete deregulation of the sympathetic nervous
system, we chose to investigate SCI-induced immune dys-
function using a low thoracic level (T9) contusion injury
model that mostly maintains the central sympathetic regu-
lation to the peripheral lymphoid organs [6, 12]. Six to
seven weeks following a thoracic (T9) SCI contusion, mice
were intranasally infected with H3N2 influenza A virus. A
comprehensive analysis of virus-specific immunity was
performed at various time points after infection and com-
pared to uninjured controls. We demonstrate that chronic
SCI causes severe morbidity and mortality in mice in-
fected with influenza A virus. Analysis of innate immune
gene expression and recruitment of inflammatory cells to
the lungs during the initial phase did not show significant
differences between uninjured and chronic SCI mice.
In contrast, both virus-specific antibody production and
CD8+ T cell responses were severely compromised in
chronically injured mice. Vaccination against influenza
prior to injury protected mice from a homologous
influenza virus challenge but did protect against infection
with a different strain of type A influenza, H1N1 (PR8),
pointing to a deficit in CD8+ T memory cells. These
studies will have broad application to our mechanistic un-
derstanding to CIDS and may contribute to novel thera-
peutic strategies to both improve neurological outcome
and reduce death related to immune-mediated complica-
tions often seen following CNS injury.
Methods
Mice and spinal cord injury
Specific pathogen-free C57BL/6J female mice (3–4 months
old and 18–20 g in weight) purchased from Jackson La-
boratory were randomized and subjected to laminectomy
and subsequent spinal cord injury (SCI) at thoracic level T9
using the Infinite Horizon Impactor at a predetermined
force of 70 kDynes, resulting in a severe contusion injury in
Animal Biosafety level 1 facility. Immediately after injury,
mice were sutured and injected subcutaneously with 1-ml
Lactated Ringer’s solution to prevent dehydration and gen-
tamicin (40 mg/kg) to prevent urinary tract infection. Sham
controls underwent a laminectomy at T9 without SCI in-
jury. The prophylactic antibiotic treatment was continued
for 7-day post-injury. Bladder expression was performed
twice daily until recovery of function. By 6- to 7-week post-
SCI, mice have usually regained their initial body weight.
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Uninjured age-matched mice were used as controls (CT).
About 1 week prior to infection, mice (SCI, CT, and Sham
mice) were transferred to animal biosafety level 2 housing
for subsequent influenza infection. All animal protocols
were approved by the University of Miami Institutional
Animal Care and Use Committee (IACUC) and are in
accordance with National Research Council guidelines
for the care and use of laboratory animals. We also report
compliance with the ARRIVE guidelines as requirement
for reporting in vivo animal experiments [19].
Influenza virus infection
Influenza virus subtypes A/HKx31 (HKx31, H3N2) and
A/Puerto Rico/8/34 (PR8, H1N1) were used for these
studies. PR8 expresses the surface protein hemagglutinin
(HA) and neuraminidase (NA) of H1N1 subtype, whereas
the reassorted HKx31 virus expresses the H3N2 surface
protein of A/Hong Kong/1/1968 but also contains six in-
ternal proteins common to the PR8 virus [20]. H3N2 via in-
tranasal route has intermediate virulence in mice compared
to PR8 and infection with either viruses results in complete
clearance by day 10 post-infection [18]. Mice were weighed
prior to viral infection and then anesthetized with a mixture
of ketamine (80 mg/kg) and xylazine (10 mg/kg) mixture.
1 × 104 plaque-forming units (PFU) of HKx31 virus in a 30-
μl volume were delivered intranasally. The dose and volume
ensure a 100 % rate of infection and mice were monitored
daily for weight loss and morbidity. PR8 virus was adminis-
tered (1x104 PFU) in the secondary infection model for
memory response studies.
Virus titer
Mice were sacrificed as per AVMA (American Veterinary
Medical Association) guidelines at various times post-
infection. Lungs were harvested, snap frozen in liquid
nitrogen, and stored in −80 °C until assayed. Viral titers
were determined from homogenized lungs using the 50 %
tissue culture infectious dose (TCID50) method [21].
Briefly, confluent Madin-Darby canine kidney (MDCK)
cells cultured in MEM (Invitrogen) containing 2-mM
L-glutamine, 10 μg/ml gentamicin, and 5 % FBS were
infected with serial dilution of lung homogenate and
incubated at 37 °C for 2 h to allow virus particles to ad-
sorb to cells. The inoculum was washed and replaced
with media containing 2 μg/ml of Tosyl Phenylalanyl
Chloromethyl Ketone (TPCK)-treated trypsin and incu-
bated for 72 h. Viral infection was scored by observing
the cytopathic effect in infected wells after staining with
crystal violet and was confirmed by hemagglutination
assay with chicken red blood cells.
RNA extraction and real-time PCR
Lungs were homogenized in TRIzol (Life Technologies)
and total RNA isolated following the manufacturer’s
protocol. An aliquot of 20 μg of total RNA was further
purified using the RNeasy mini kit (Qiagen) with on-
column DNase digestion to remove any trace of genomic
DNA contamination. cDNA was obtained by reverse tran-
scription of 1 μg of purified RNA using the Omniscript RT
kit (Qiagen) and analyzed by quantitative real-time PCR
using primer pairs as shown in Additional file 1. For each
gene, a standard curve was obtained by diluting defined
amounts of the target PCR product. All the data obtained
were normalized to β-actin gene expression levels.
Flow cytometric analysis of innate immune cells in BAL
Mice were sacrificed, and bronchoalveolar lavage (BAL)
cells were collected by flushing the exposed trachea after
cannulation with an 18-gauge, ½-in. cannula connected
to a 1-ml syringe. The BAL cells were harvested by flush-
ing the lungs with 10 % 1XRPMI and centrifugation. The
cells were resuspended for flow cytometric analysis in ap-
propriate stains. They were first blocked with anti-CD16/
32 (FcR block, eBiosciences) to prevent non-specific stain-
ing and then stained with APC Cy7-anti-F4/80 (clone
BM8, Biolegend), PE Cy7-anti-CD11b (clone M1/70,
eBioscience), APC-anti-CD11c (clone N418, Biolegend),
and FITC-anti-Gr1 (clone RB6-8C5, BD Pharmingen) and
gated according to Hall et al. [22]. Briefly, cells were first
gated as F4/80+ or F4/80− cells. F4/80+ cells that are
CD11bhigh were referred to as macrophages and those that
are CD11chigh/CD11blow as alveolar macrophages. DCs
were gated as F4/80low CD11chigh and monocytes as F4/
80low CD11clowCD11bmid. Finally, neutrophils were gated
as F4/80low CD11clowCD11bhigh and Gr1high. Data were
collected using the LSRII flow cytometer and analyzed
with FACSDiva 6.1 software (BD Biosciences).
ELISA for virus-specific antibody
Sera were collected by arterial bleed, and BAL superna-
tants were harvested from the lungs after flushing once
with 0.5 ml 10 % 1xRPMI followed by centrifugation at
1000 rpm for 5 min. Samples were frozen at −80 °C for
virus-specific antibody assays. Influenza-specific antibody
levels in sera and lung washes were determined by ELISA
[23] with an inactivated influenza HKx31, A/Aichi/68
(H3N2) virus (Charles River Laboratories). Briefly, the
virus was inactivated with 0.5 % Triton X-100 and coated
on plates overnight at 4 °C. Next day, the plates were
washed with PBS/0.05 % Tween 20 (Sigma) and blocked
with 1 % BSA in PBS for 1 h at room temperature. Serial
dilutions of BAL and serum samples were added to the
wells and incubated for 2 h at room temperature. After ex-
tensive washes, influenza-specific antibodies were detected
with the corresponding HRP-conjugated goat anti-mouse
IgG, IgM, or IgA fraction (1:1000, Southern Biotechnology
Associates). Color development was performed with
TMB (3,3′,5,5′-tetramethylbenzidine) substrate (Sigma)
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for 60 min at room temperature and read at 450 nm in
an ELISA reader (Molecular Devices).
B cell activation assay
Lymphocytes were isolated from spleens as previously
described [11]. Mature resting B cells were isolated by
depletion of CD43+ cells using CD43 (Ly-48) MicroBe-
ads according to the manufacturer’s protocol (Miltenyi
Biotec). B cells (106/well) were cultured in 1 ml of complete
RPMI (RPMI 1640, 5 % FBS, 100 U/ml penicillin, 100 μg/
ml streptomycin) in a 24-well plate with 5 ng/ml of recom-
binant mouse IL-4 (Gibson) and 5 μg/ml of anti-mouse
IgM (Jackson ImmunoResearch Laboratories) for 24 h. B
cells cultured in 1-ml complete RPMI were used as the un-
stimulated control. Both stimulated and unstimulated B
cells were harvested and washed with FACS buffer and
were incubated with 5 μg/ml Fc receptor block (anti-mouse
CD16/32, Biolegend) for 5 min on ice. Cells were then
stained with antibodies including APC-efluor780-anti-B220
(eBiosciences, clone HIS24, 1:200), PE-anti-CD86 (Bio-
legend, clone GL-1, 1:200), APC-anti-MHC class II
(eBiosciences, clone M5/114.15.2, 1:1000), and PE/Cy7-
anti-CD40 (Biolegend, clone 3/23, 1:50). Cells were de-
tected using LSRII and analyzed by FACS-Diva Version
6.1.3 software (BD Biosciences).
Virus neutralization assay
Serum samples diluted twofold were mixed in equal vol-
umes with 100 TCID50 of HKx31 (H3N2) for 2 h at 37 °C
in a 5 % CO2 atm. The virus/serum mixtures were then in-
cubated on MDCK cell monolayers in 96-well plates for
another 2 h. The cells were washed and maintained in
TPCK-containing medium, and infected wells were identi-
fied by hemagglutination assay after 3 days.
Tetramer and intracellular cytokine assay
The kinetics and magnitude of the virus-specific CD8+ T
cell responses were analyzed by flow cytometry. Spleens
were harvested and processed according to published
methods [24]. Lymphocytes were isolated from spleens
after dissociation and subjected to red blood cell lysis
with ammonium-chloride-potassium (ACK) buffer (Invi-
trogen). Virus-specific CD8+T cells were quantified by
staining cells for 1 h at room temperature with H-2Db
MHC Class I (C57Bl/6J mice) tetramers [25] conjugated
to either PE or Alexa488 DbNP366, ASNENMETM [26]
or PE or APC labeled DbPA224, SSLENFRAYV [27] ob-
tained from the NIH Tetramer Facility (Emory University,
Atlanta). The cells were washed extensively with FACS buf-
fer (PBS, 1 % BSA, 0.05 % azide) and were surface stained
with FITC-conjugated anti-CD8α (clone 53-6.7, BD Phar-
mingen). For intracellular cytokine assays, lymphocytes
were cultured in 96-well round-bottom plates for 6 h at
37 °C in the presence of brefeldin A (Enzo LifeScience) with
either 1-μM NP366 or 1-μM PA224 peptide. The cells were
next stained with FITC-labeled anti-CD8 (clone 53-6.7) for
30 min and fixed. Intracellular cytokines were detected with
PE IFNγ (clone XMG1.2, BD Pharmingen), APC TNF
(clone MP6-XT22, BD Pharmingen), and PE-Cy7 granzyme
B (clone NZGB, eBiosciences) after permeabilization. Cells
were resuspended in FACS buffer, and data was acquired
with LSR II (BD Biosciences). A total of 10,000 CD8+ T
cells were analyzed using FlowJo software (Tree Star) for
calculating the numbers of virus-specific CD8+ T cells.
Vaccine study
Mice were vaccinated with inactivated HKx31 (H3N2)
vaccine (Charles River Laboratories) prior to injury and
challenged with homologous (same strain, H3N2) or
heterologous (different strain, H1N1) viruses to define
whether injury alters virus-specific memory cells. Briefly,
8- to 10-week old mice were immunized by intramuscular
injection into the tibialis inferior muscle of each limb with
a total dose of 10 μg of vaccine, given in two injections
(each 5 μg in 50 μl of PBS). A booster dose was adminis-
tered into the same muscle 2 weeks later. Serum was col-
lected 2 weeks after the second dose and assayed for
virus-specific IgG by ELISA (as described above) prior to
SCI. Seven weeks post-injury vaccinated injured and unin-
jured mice were infected intranasally with 1x104 PFU of
the same strain of live virus as the vaccine (H3N2) and
monitored daily for survival. Since these studies were lon-
ger in duration compared to the primary infection model,
age-matched non-vaccinated injured and uninjured mice
were also infected as secondary controls. Virus-specific
antibodies were monitored 10 and 30 days post-infection
by IgG ELISA and neutralization assay. Surviving mice in
the vaccinated groups were further challenged intranasally
a month later with high dose (1x104 PFU) of heterologous
virus (H1N1, PR8) to test whether these mice were able to
recover from infection with a new strain of virus.
Statistical analyses
ANOVA, with Bonferroni post-test, was used to compare
differences between groups. A Student’s t test was used to
compare each time point within each group. Comparison
of survival curves following infection was performed using
the log-rank (Mantel-Cox) test. GraphPad Prism (Graph-
Pad Software, La Jolla Ca, USA) was used for statistical
analysis. Statistical significance was inferred when p ≤ 0.05.
Results
Impaired viral clearance increases mortality in chronically
injured mice
Infection with 1x104 PFU dose of H3N2 in immunocompe-
tent C57BL/6J mice establishes a robust influenza-specific
immunity that clears virus by 10-day post-infection (dpi)
[28]. In Fig. 1, we report the effect of virus infection with
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respect to viral titers and survival of SCI mice in compari-
son to sham-operated and uninjured control (CT) mice.
The data presented in Fig. 1b demonstrates that viral infec-
tion was established uniformly 5 dpi in the lungs of all three
groups. No statistical differences in viral titer were observed
between groups (CT 5.67 ± 0.3, SCI 6.25 ± 0.7, Sham 5.62 ±
0.17, Log10TCID50/ml). However, on 10 dpi, while all CT
mice cleared the virus, seven out of ten mice in the SCI in-
jured group did not clear the virus and continued to have
high titers of infectious virus in their lungs (3.13 ± 0.8
Log10TCID50/ml). Most of the sham-operated controls (6/
8) cleared the virus, and both animals had significantly
lower virus titer than the SCI group (Sham 0.5625 ± 1.24,
SCI 3.13 ± 0.8 Log10TCID50/ml) indicating that the defect
in viral clearance was due to spinal cord injury. Survival of
mice (n = 27 SCI, n = 24 CT, n = 8 Sham) after virus infec-
tion was monitored in a second experiment for 10 days. As
shown in Fig. 1c, 38.2 % of SCI mice succumbed to infec-
tion (p < 0.001, log-rank Mantel-Cox test).
Maintenance of innate response in chronic SCI mice
The innate immune system is considered as the first line
of defense against viral infections. At the initial stage of
infection, innate immune mechanisms in the lungs initiate
antiviral responses including expression and secretion of
cytokines and chemokines subsequent to attachment of
viral particles to specific pattern recognition receptors
[29]. The release of proinflammatory mediators recruits a
rapid influx of neutrophils, monocytes, and natural killer
(NK) cells to the site of infection and is pivotal for clear-
ance of virus-infected cells [30]. To begin investigating the
innate immune responses after influenza infection, we
used qPCR to examine mRNA expression of antiviral
genes, cytokines, and chemokines from the lungs, of in-
fected chronic SCI mice and aged-matched controls at 0,
2, and 4 dpi. We chose the following genes based on their
known activity in the antiviral response: interferon beta
(IFNβ), interferon regulatory factor 9 (IRF9), monocyte
chemotactic protein 1 (CCL2/MCP1), interferon gamma-
induced protein 10 (CXCL10/IP-10), and macrophage in-
flammatory protein-1β (CCL4/MIP-1β) [31]. There was
no statistical difference in the levels of gene expression of
any of the cytokine/chemokine between chronic SCI and
control groups (Fig. 2a). We also show that the virus-
specific M1 gene (matrix) is expressed in the lungs of CT
and chronic SCI mice confirming that there was no im-
pairment of establishment of virus infection (Fig. 2a).
The composition of innate immune cells was assessed
on 2 and 4 dpi from lung lavage of individual mice. In
response to H3N2 influenza infection, both uninjured
and chronic SCI mice had an increase in the appearance
of innate immune effector cells including neutrophils, al-
veolar macrophages, and myeloid-derived dendritic cells
(DC) into the airway as reflected by the numbers of cells
present over time (Fig. 2b). By far, the largest number of
cells were neutrophils and monocytes (CD11b+CD11c-)
followed by the conventional DC (CD11+CD11c+), macro-
phages (F4/80+ and CD11bhigh), and alveolar macrophages
Fig. 1 Impaired viral clearance in spinal cord injured mice. a Schematic of the experiment. Mice received a spinal cord injury (SCI) or laminectomy
(Sham) at thoracic level T9 and 7 weeks later were infected intranasally with 1 × 104 H3N2 (x31) influenza particles. An age-matched uninjured control
group (CT) and a group receiving only a T9 laminectomy without injury were also infected and served as controls. Lungs were harvested 5- or 10-day
post-infection for virus titer. b Viral titers were determined from lung homogenates isolated on day 5 and 10 post-infection. While all control uninjured
mice cleared the virus, chronic SCI mice still had active virus in their lungs (mean ± SEM, 3 mice/group d5 and 10 mice/group d10, two-way ANOVA,
**p < 0.01). Most of sham-operated mice had cleared the virus by day 10 (n = 8). ND not detectable. c Cumulative survival curves showed a significant
increase in mortality among mice receiving a spinal cord injury compared to CT or Sham. Twenty-four to twenty-seven mice per group for CT and SCI,
8 mice/group for Sham, log-rank test, **p < 0.01
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(CD11chigh/CD11blow). The ability of all of these cell types
to control viral replication and the development of adap-
tive immunity is well established [32]. Thus, virus-specific
innate immunity within the lungs of chronically injured
mice is not compromised.
Reduction in virus-specific antibodies in chronic SCI mice
Virus-specific antibodies and cytotoxic CD8+T cells are
key components of the adaptive immune that are neces-
sary to clear virus infection [33]. These antibodies are
rapidly induced early during primary infection [34]. Mu-
cosal IgA generated in the respiratory tract prevents
virus attachment, whereas systemic IgG is required to
prevent infection either by neutralization of virus infect-
ivity or antibody-dependent cell-mediated cytotoxicity
(ADCC) or complement-mediated lysis [35]. Various iso-
types of virus-specific antibodies were analyzed in CT and
chronic SCI mice using standardized ELISA. Chronic SCI
mice demonstrated a significant reduction in virus-specific
IgM on 5 dpi (p < 0.05) and 7 dpi (p < 0.001) post-
infection in the serum compared to uninjured CT (Fig. 3a).
In addition, both IgG and IgA were also diminished in
chronic SCI mice (Fig. 3a) on 7 dpi. Similarly, mucosal
IgA responses in SCI mice were reduced significantly
(Fig. 3b) in comparison to CT. Individual sera were further
tested using a virus neutralization assay to evaluate
whether virus-specific antibodies were able to block virus
infection. Negligible neutralizing activity was seen early in
infection on day 5 in both groups. However, on 10 dpi, all
of the mice from the uninjured CT group had a virus
neutralization titer of 1:40 whereas none of the sera iso-
lated from chronic SCI mice had neutralizing activity
(Fig. 3c). In the chronic SCI group, neutralization was not
detected at a serum dilution of 1:10, which is the limit of
detection for this assay.
Splenic B cells from chronic SCI mice are functional
Since we showed a deficit in a humoral immune re-
sponse with reduced virus-specific antibody production
and neutralization activity, we tested the possibility that
B cells from chronic SCI mice are functionally impaired
7-week post-injury before infection. First, we examined
the distribution of B cells into different subsets, (follicu-
lar (FO), marginal zone (MZ), intermediate (Inter.), and
age-associated B (ABC) cells) by flow cytometry (Fig. 4).
We did not find any significant differences in either the
frequency or the number of these B cells (Fig. 4a, b).
We next assessed their function in vitro by stimulating
Fig. 2 Early response to influenza in the lungs of spinal cord injured mice is not altered. a Expression of proinflammatory cytokines (CCL2,
CXCL10, CCL4) and antiviral genes (IFNβ and IRF9) was examined in the lungs of chronic SCI and uninjured control mice prior to infection (d0)
and 2- and 4-day post-infection using quantitative real-time PCR. Data are expressed as percent of uninjured control at d0 (mean ± SEM, 4 mice/
group). In addition, we assessed the levels of virus using qPCR for the matrix 1 (M1) influenza gene at d2 and d4 post-infection. Data represents
mean ± SEM (4 mice/group). b Innate immune response in the lungs of both CT and chronic SCI H3N2-infected mice was assessed by flow cytometry
using the differential expression of markers F4/80, CD11b, CD11c, and Gr1 according to Hall et al. [22]. Bars represent the mean ± SEM
(4 mice/group)
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them with both anti-IgM and IL4, which mimics BCR-
dependent activation (Fig. 4c). As expected following
stimulation, expression of CD86, CD40, and MHCII
was significantly increased compared to unstimulated
controls. However, activation levels between CT and
chronic SCI B cells were not statistically significant
suggesting that B cells from injured mice are not intrin-
sically impaired. This further suggests that the impair-
ment observed in vivo may be due to deficits in antigen
presentation and/or CD4+T helper cells [36].
Decrease in virus-specific CD8+T cells in injured mice
CD8+T cells (cytotoxic T lymphocytes, CTL) play an im-
portant role in influenza-infected lungs by destroying
viral-infected cells via perforin/granzyme-dependent gran-
ule exocytosis as well as by FasL/Fas-mediated apoptosis
following T cell receptor (TCR) engagement [37]. Secretion
of proinflammatory cytokines (e.g., IFNγ and TNFα) is hall-
marks of these CTLs which contributes to the recruitment
and activation of innate inflammatory cells, in particular, in-
flammatory CD11chi DC and pDC [38]. The infectious
virus recovered from infected injured mice on day 10
(Fig. 1b) indicates that CTL response to influenza antigens
may also be compromised in chronic SCI. We therefore
quantified the number of virus-specific CD8+T cells and
their ability to produce intracellular cytokine IFNγ and/or
TNFα day 7 after infection. Figure 5a demonstrates that
chronic SCI mice had a significant (p < 0.05) reduction of
virus-specific CD8+T cells of 6.5-fold in PA-specific cells in
the spleen compared to infected uninjured controls. Im-
portantly, the total numbers of CD8+T cells recovered from
both groups of mice were not significantly different (CT
3.9 ± SD1.6; SCI 3.0 ± SD2.0; x106) and therefore recruit-
ment of these cells in response to infection was not defect-
ive. Next, the ability of these CD8+T cells to secrete
antiviral cytokines was analyzed as a qualitative measure of
virus-specific CD8+T cell function by intracellular cytokine
assay after in vitro stimulation in culture for 6 h with virus-
specific MHC class I restricted peptides NP366–374 and
PA224–236. The numbers of CD8
+T cells producing IFNγ or
both IFNγ and TNFα were significantly reduced or were
not detectable in chronic SCI mice compared to CT
(Fig. 5b, c). Furthermore, the percentage of PA224–236 virus-
specific CTL producing granzyme B, an effector molecule
to initiate cell death in virus-infected cells was also sig-
nificantly reduced in chronic SCI compared to uninjured
controls (Fig. 5d).
Vaccination prior SCI generates protective immunity
Our data show that adaptive immunity against influenza
virus is severely attenuated in chronic T9 SCI mice dur-
ing primary infection. Therefore, we asked the question
whether antigen-specific memory obtained through vac-
cination prior to spinal cord injury would protect mice
against a homologous viral infection. This has clinical
implications since SCI patients are either vaccinated prior
to injury or will receive yearly flu vaccine as a standard of
care to prevent flu-associated morbidity and hospitalization
Fig. 3 Impaired antibody response to influenza in chronic SCI mice. a Influenza virus-specific antibody response was assessed by ELISA using
H3N2 virus-coated plates and diluted sera from chronic SCI and CT mice 5 or 7 days post-infection. Bar graphs represent the mean ± SEM,
5 mice/group. Data was normalized after subtracting the values from uninfected mice from both the uninjured and injured groups at day 0
prior to infection. b Virus-specific IgA response was measured in the BAL of infected mice on day 5 and day 7. Mean ± SEM, 5 mice/group.
c The ability of the antibodies to neutralize the virus was tested using serial dilutions of the serum from uninjured CT and SCI mice
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[39]. As shown in Fig. 6a, mice were injected intramuscu-
larly with two doses of inactivated H3N2 (HKx31) virus be-
fore sustaining a spinal cord injury at thoracic level T9.
Seven weeks later, mice were challenged with the same
virus and monitored daily for survival until day 30 post-
infection. All vaccinated chronic SCI mice (SCI-Vaccine)
survived influenza infection to the same extent as vacci-
nated uninjured CT mice (CT-vaccine) and non-vaccinated
uninjured CT mice (CT-PBS) (100 % survival, Fig. 6b). This
was in sharp contrast to non-vaccinated chronic SCI mice
(SCI-PBS) where survival rate dropped to 77 % (day 7) and
11 % (day 10).
We next analyzed sera for virus-specific IgG produc-
tion and neutralizing activity from all groups to confirm
vaccine responses. Sera from non-vaccinated chronic
SCI mice (SCI-PBS) had low levels of virus-specific IgG
and did not neutralize virus infectivity compared to unin-
jured controls (data not shown). In contrast, vaccinated
Fig. 4 Intrinsic function of B cells is preserved in chronically injured mice. a, b The frequency and number of splenic mature B cell subtypes in
chronic SCI mice (SCI) are not statistically different from uninjured mice (CT). a Splenocytes from chronic SCI mice were isolated 7-week post-injury
along with age-matched uninjured CT. Mature B cells were gated as CD19+IgM+AA4.1−CD43− B cells and then further subdivided into follicular (FO,
CD23+CD21+), marginal zone (MZ, CD23−CD21hi), intermediate (Inter., CD23−CD21lo), and age-associated B cells (ABC, CD23−CD21−). Data in the table
represent the % of B cells in the different subsets (mean ± SEM, n= 4/group). b Bar graphs represent the total cell number for each subset of B cells
(mean ± SEM, n = 4/group), calculated from the percentages obtained in A. c Functional in vitro assay on isolated splenic B cells from chronic SCI and
uninjured CT mice. Cells were stimulated with anti-IgM and IL4 or left unstimulated. B cell activation was analyzed by the surface expression of CD86,
CD40, and MHCII markers by flow cytometry, and the data is represented as mean fluorescence intensity (MFI)
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SCI group (SCI-Vaccine) produced a similar amount of
virus-specific IgG as the vaccinated CT mice (Fig. 6c). Im-
portantly, chronic SCI-vaccine mice had high levels of
virus neutralizing activity (Fig. 6d) similar to the CT-
vaccine group, which correlated with their 100 % survival.
Spinal cord injury impairs the virus-specific memory T cell
response
Vaccination with an inactivated virus is designed to
generate protective antibodies primarily against the
hemagglutinin (HA) surface protein of the viral par-
ticle [40]. However, influenza viruses undergo genetic
mutations such as drift or shift that contribute to the
generation of viruses that can escape neutralizing anti-
bodies, or give rise to new viruses to which, there is no
pre-existing antibodies (leading to a potential pandemic)
[41]. In these instances, cross-reactive memory T cells tar-
geted to conserved internal proteins can provide immune
protection between two different virus strains [42]. In order
to investigate whether the virus-specific compartment-cell
memory was functional after chronic SCI, we re-challenged
both CT and SCI vaccinated groups 2 months after the
H3N2 (HKx31) infection with a high dose (1x104 PFU)
of H1N1 (PR8) virus by intranasal infection. H3N2 and
H1N1 viruses share the same internal proteins and generate
robust CD8+T cell immunity against a number of viral pep-
tides. In immunocompetent mice, these memory T cells
mediate cross-reactive memory T cell responses that clear
the virus earlier [43]. As shown in Fig. 6e, while CT mice
were protected against a second challenge, only 60 % of
chronic SCI mice survived at day 9 post-infection and 40 %
at day 15. High virus titers were recovered from the lungs
of mice succumbing to infection (data not shown). Thus,
cross-reactive T cell memory responses to a heterologous
challenge was impaired after chronic SCI indicating that
injury can also permanently damage memory-specific T
cell responses to new influenza virus infections.
Discussion
Patients with SCI live for years and suffer from significant
morbidity due to recurrent respiratory infections. We
therefore hypothesized that chronic immune paralysis after
SCI would impair virus-specific host immunity. Using both
primary and secondary infection models of influenza infec-
tion, we report this study is the first to demonstrate that
thoracic T9 spinal cord injury alters the adaptive immune
response directed against a clinically important influenza A
respiratory virus.
Crosstalk between the nervous system and the immune
system plays a pivotal role in maintaining homeostasis of
Fig. 5 Spinal cord-injured mice produce significantly less virus-specific CD8+T cells than CT mice. a Splenocytes from naïve and SCI mice isolated
7-day post-infection were analyzed by flow cytometry using tetrameric complexes of either the nucleoprotein peptide (NP366–374) or the polymerase 2
protein peptide (PA224–233) presented by class I H-2D
b (mean ± SEM, 4–5 mice/group, *p < 0.05). b, c In vitro intracellular cytokine assay revealed a
significant decrease in the number of CD8+T cells producing IFNγ following stimulation with the peptide DbNP366 (b) and a significant decrease in the
number of CD8+T cells producing IFNγ as well as both IFNγ and TNF following stimulation with the peptide DbPA224 (c). d Percentage of CD8+T cells
expressing granzyme B, TNFα, and IFNγ following stimulation with peptide DbPA224. Bar graphs represent the mean ± SEM, n = 4–5 mice/group,
*p < 0.05
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the host. This coordination is achieved via the sympathetic
nervous system (SNS) and the hypothalamic-pituitary-axis
(HPA), which regulates a variety of cytokines, hormones,
and neurotransmitters [44, 45]. Thus, direct injury to
the neural pathways innervating the spinal cord con-
tributes to functional deficit in the peripheral immune
response and renders patients with SCI more susceptible
to viral and bacterial infections [46]. Indeed, patients with
longer duration of SCI have higher frequency of respira-
tory infections, which increases with aging [14]. We report
here for the first time that chronic SCI alters the adaptive
immunity to influenza, an important human respiratory
virus, in a thoracic level T9 spinal cord contusion model.
Level of injury
We used a thoracic T9 level of injury for the following
reasons. First, several studies looking at the effects of
SCI on the immune system have compared high thoracic
(T3) versus low thoracic (T9) level of injuries and found
that T3 injury has a greater disruptive effect on the HPA
and SNS axis than a lower thoracic level T9 [6] with T3
injury being more detrimental to B cell function compared
Fig. 6 Vaccinated chronic SCI mice are protected from a strain-matched influenza virus but not from a second challenge with a different strain.
a Schematic of the experiment. Mice were divided into two groups (n = 15/group): one group received two doses of inactivated H3N2 vaccine
and the other PBS 1 month prior to SCI. The two groups were further divided into two sub-groups, one receiving a spinal cord injury at thoracic
level T9 (SCI, n = 10) and the other was not injured (CT, n = 5). Seven weeks post-injury, all mice were infected with H3N2 (HKx31) by intranasal
route. Blood samples (open circles) were collected 4 days before SCI to confirm that all vaccinated mice had developed influenza-specific antibody
titer and at day 0, 10, and 30 post-infection. The two groups of vaccinated mice (CT-vaccine, n = 5 and SCI-vaccine, n = 10) were challenged a
second time with a different influenza strain, H1N1 (PR8). b Survival curve for the four groups of mice (n = 5/group for CT and 10/group for SCI)
infected with H3N2 (HKx31). Only the chronic SCI mice that were not vaccinated (SCI-PBS) showed a dramatic decrease in survival. ****p < 0.0001,
log-rank (Mantel-Cox) test. c The virus-specific antibody response in vaccinated SCI mice was similar to that of the vaccinated CT group (n = 5).
**p < 0.01, ***p < 0.001. d Chronic SCI mice previously vaccinated produced neutralizing antibodies to the virus to the same extent as uninjured
CT mice. *p < 0.05, **p < 0.01. e Vaccination of chronic SCI mice does not protect against a second challenge with a different influenza strain.
Survival curves of H3N2-vaccinated uninjured CT (n = 5) and chronic SCI mice (n = 10) challenged with a dose of H1N1 virus. ****p < 0.0001,
log-rank (Mantel-Cox)
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to T9 [4, 9, 10]. Despite those differences, mice sustaining
T9 SCI were as sensitive to mouse hepatitis virus (MHV)
infection and mortality as T3 spinal cord injured mice [4].
Second, we showed in our previous study that mice sus-
taining a lower thoracic T9 SCI display deficits in T cell
function 7-week post-injury accompanied by increased
levels of splenic norepinephrine that contributed to the
exhausted phenotype and dysfunction of those T cells [11].
Third, T3 injury will affect respiratory capacity to a greater
extent than T9 injury [47] and would add another layer of
complexity in the influenza infection model. Lastly, pa-
tients with lower thoracic injury are more active and
may be more exposed to pathogens, which would in-
crease their susceptibility to respiratory viruses such as
influenza transmitted by aerosolized contact.
Influenza infection
The immune response to influenza infection provides a
model to systematically study the contributions of host
immunity by addressing both innate and adaptive com-
partments. We demonstrate that primary infection with
influenza A virus of chronically injured mice (7-week
post-SCI) at thoracic level T9 causes severe morbidity
and mortality. Approximately 40 % of injured mice suc-
cumbed to infection (Fig. 1c) and 60 % of the injured
mice had high viral titers in their lungs on 10 dpi when
compared to uninjured control or sham-operated animals
(Fig. 1b). Our data are in agreement with the study done by
Held and colleagues [4] where increased mortality was ob-
served in T9-injured mice infected with a mouse hepatitis
virus (MHV), 4-week post-injury compared to uninjured
control mice. However, in contrast to our study, an increase
in MHV titer in the liver of SCI group was observed early
in infection in comparison to uninjured mice. We did not
find any significant difference in viral load on day 5 during
the establishment of virus replication (Fig. 1b) in injured,
uninjured, and sham mice, which is indicative of SCI injury
not exacerbating the viral infection per se. This was also
confirmed by the ability of chronic SCI mice to mount an
innate immune response as demonstrated by the significant
increase in the expression of antiviral genes and the
presence of innate immune effector cells in the airways
of both influenza virus-infected CT and chronic SCI
mice (Fig. 2a, b).
The adaptive immune system comprising of humoral
and T cell-mediated immunity plays a crucial role in
controlling respiratory virus infections such as influenza
[17]. The virus-specific antibodies are targeted to two
outer surface glycoproteins namely hemagglutinin (HA)
and neuraminidase (NA) both of which are predicted to
correlate with protection [48] and recovery from lethal
infections [49]. The main antibody isotypes produced
during influenza infection are IgA, IgM, and IgG in
serum with secretary IgA being more prominent at the
local site of replication [17]. Influenza-specific IgM initi-
ates neutralization of the virus by complement-mediated
system, and IgG is required for generation of long-lived
protective antibodies. Mucosal IgA is required for neu-
tralizing the virus at the site of replication and mediating
cross-protection against drift viruses with the same sub-
type [50]. Thus, cumulative deficits in all virus-specific
isotypes seen as early as 5 dpi in chronic SCI mice may
contribute to the impaired viral clearance on 10 dpi.
Surprisingly, there was no difference between chronic
SCI and uninjured control mice in the percentages of
various subsets of B cells or their activation following
in vitro stimulation prior to infection indicating no in-
trinsic impairment in B cell function and pointing to a
possible deficit in CD4+T helper function to thymus-
dependent responses and germinal center reaction
after infection. The requirement of CD4+T cell helps
for thymus-dependent responses, and germinal center
reaction during primary infection [51, 52] is well
known and merits further investigation in this chronic
SCI model.
The importance of virus-specific CD8+T (CTLs) cells
during influenza infection is also well documented
[37, 53, 54]. During primary infection, CTLs traverse
to the site of infection and eliminate virus-infected
targets and upon re-infection with different subtypes
of influenza viruses; these CTLs can provide cross-
protection as their specificity is generally derived from
conserved internal viral proteins [55]. In chronic SCI
mice, CD8+T cells restricted to conserved proteins of the
virus were reduced both quantitatively and qualitatively in
spleens during primary infection in comparison to CT
animals. The repertoire of influenza CTLs in response
to human infection is also targeted to these internal
proteins [56], and therefore understanding these mech-
anisms in mouse infection models of SCI will allow us
to design targeted therapy. Mechanistically, our data
imply that injury may alter the presentation of viral an-
tigens by splenic antigen presenting cells to CD8+T
cells located at the T cell zones. One can also infer from
our published work that accumulation of norepinephrine
within the spleen at the chronic phase promotes immune
suppression as both T and B cells express neuroendocrine
receptors [11]. Future studies are in progress to test these
hypotheses.
Vaccination and challenge with homologous and
heterologous influenza virus strains
We next asked the question whether intramuscular vac-
cination with whole inactivated H3N2 virus adminis-
tered before injury would protect chronic SCI mice from
a subsequent homologous infection. Our results show that
previously vaccinated chronic SCI mice are protected from
a secondary challenge with the same influenza strain,
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displaying high levels of virus-specific antibodies that
neutralize virus infectivity and control mortality. Likewise,
in a mouse model of chronic SCI, Oropallo and colleagues
demonstrated that secondary humoral immunity remains
functional and can be boosted after injury [10]. Collect-
ively, our data confirms that pre-existing vaccine-specific
B cell memory does not require neuronal regulation, is re-
fractory to CNS-mediated changes of HPA axis, and thus
has implication for influenza vaccination in SCI patients.
In contrast, memory-specific CD8+T cells generated after
injury were compromised in chronic SCI mice heterol-
ogous virus challenge model affirming that injury causes
permanent damage to the peripheral immune response to
pathogen-specific immunity even at T9 level. This obser-
vation also provides us with further opportunity to assess
the role of CD4+T cells in this model in the future, as it is
known that in comparison to primary infection, CD4+T
cells play a pivotal role on the size and magnitude of
CD8+T cells during a recall response [52, 57].
Conclusions
We conclude that virus-specific adaptive immune response
is severely hampered in chronic SCI mice using a mouse
model of influenza infection. Furthermore, we provide evi-
dence that chronic SCI also affects the formation of im-
munological memory in a secondary virus infection model.
To our knowledge, this is the first comprehensive analysis
of innate and adaptive immune response against a clinically
relevant respiratory pathogen in a chronic SCI preclinical
model. A concerted effort is underway to analyze suscepti-
bility to infections in patients using the National Spinal
Cord Injury Database [58]. Thus, future research using
virus infection models will allow us to dissect mechanisms
of how injury to the CNS weakens peripheral immunity
and whether specific treatments can be designed to im-
prove outcome of SCI patients following infection.
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